Healthcare
Phibro Animal Health Corporation(PAHC)
Live Price
Offline$31.85
+3.27% today
1Y Change
+26.71%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $2.22B
- Revenue Growth
- +27.4%
- EPS Growth
- +1883.3%
- Dividend Yield
- 0.9%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Phibro Animal Health Corporation (PAHC) is a Healthcare stock with a market cap of $2.22B and listed on NASDAQ. The stock last traded around $31.85 and up 26.7% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +27.4%, EPS growth of +1883.3%, a dividend yield of 0.9%. What stands out right now is revenue +27.4%, EPS +1883.3%, free cash flow -9.8% with operating margin 11.6% and ROIC 10.7%. The dividend is present but secondary, with a yield around 0.9%. Valuation is more restrained than many high-expectation growth names at P/E 24.2 and price/sales 1.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PAHC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+27.4% vs +7.6% peer median
Operating Margin
Below sector median
+11.6% vs +19.4% peer median
P/E
Below sector median
24.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +27.4% and EPS at +1883.3%, with operating margin around 11.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -26.2% | -39.7% | -43.5% |
2026 Feb 4, 2026 | +26.1% | +22.0% | +25.7% | +21.0% |
2025 Nov 5, 2025 | +23.7% | +4.6% | +10.1% | -0.9% |
Benchmark Edge
PAHC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
PAHC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
PAHC Max Drawdown
-52.13%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PAHC and SPY.
Company Overview
Phibro Animal Health Corporation
NASDAQ Global Market
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
- Leadership
- Jack Clifford Bendheim
- IPO Date
- Apr 11, 2014
- Employees
- 1.9k
- Street Address
- Glenpointe Centre East
- Mailing
- Teaneck, NJ, 07666-6712
- Region
- Teaneck, NJ, US
- Reporting Currency
- USD
- Investor Line
- 201 329 7300
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 24.2
- EV/EBITDA
- 13.0
- Price/Sales
- 1.5
- Price/Book
- 6.7
Growth
- Revenue
- +27.4%
- EPS
- +1883.3%
- Free Cash Flow
- -9.8%
Profitability
- Gross Margin
- 31.9%
- Operating Margin
- 11.6%
- Net Margin
- 6.3%
- ROE
- 30.8%
- ROIC
- 10.7%
Balance Sheet
- Debt/Equity
- 2.33
- Current Ratio
- 3.05
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.